PL2138512T3 - Humanizowane przeciwciała anty-NGF - Google Patents

Humanizowane przeciwciała anty-NGF

Info

Publication number
PL2138512T3
PL2138512T3 PL09008366T PL09008366T PL2138512T3 PL 2138512 T3 PL2138512 T3 PL 2138512T3 PL 09008366 T PL09008366 T PL 09008366T PL 09008366 T PL09008366 T PL 09008366T PL 2138512 T3 PL2138512 T3 PL 2138512T3
Authority
PL
Poland
Prior art keywords
cdr
amino acid
acid sequence
humanized anti
heavy chain
Prior art date
Application number
PL09008366T
Other languages
English (en)
Inventor
Antonio Cattaneo
Sonia Covaceuszach
Doriano Lamba
Original Assignee
Abbott Res Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Res Bv filed Critical Abbott Res Bv
Publication of PL2138512T3 publication Critical patent/PL2138512T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
PL09008366T 2003-12-24 2004-12-23 Humanizowane przeciwciała anty-NGF PL2138512T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000601A ITRM20030601A1 (it) 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP09008366A EP2138512B8 (en) 2003-12-24 2004-12-23 Humanized anti-NGF antibodies
EP04806887A EP1709076B1 (en) 2003-12-24 2004-12-23 Method for the humanization of antibodies and humanized antibodies thereby obtained

Publications (1)

Publication Number Publication Date
PL2138512T3 true PL2138512T3 (pl) 2012-09-28

Family

ID=34708536

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09008366T PL2138512T3 (pl) 2003-12-24 2004-12-23 Humanizowane przeciwciała anty-NGF
PL10003283.8T PL2218737T3 (pl) 2003-12-24 2004-12-23 Humanizowane przeciwciała anty-NGF

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10003283.8T PL2218737T3 (pl) 2003-12-24 2004-12-23 Humanizowane przeciwciała anty-NGF

Country Status (19)

Country Link
US (7) US8296079B2 (pl)
EP (4) EP1709076B1 (pl)
JP (4) JP4652341B2 (pl)
CN (2) CN101724070B (pl)
AT (1) ATE534665T1 (pl)
AU (4) AU2004303633B2 (pl)
BR (1) BRPI0418202A (pl)
CA (2) CA2688944C (pl)
CY (2) CY1112611T1 (pl)
DK (3) DK1709076T3 (pl)
ES (2) ES2559429T3 (pl)
HU (1) HUE027475T2 (pl)
IL (2) IL176495A (pl)
IT (1) ITRM20030601A1 (pl)
PL (2) PL2138512T3 (pl)
PT (2) PT2218737E (pl)
SI (2) SI2138512T1 (pl)
WO (1) WO2005061540A2 (pl)
ZA (1) ZA200605200B (pl)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
ES2829566T3 (es) 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
PT1976880T (pt) * 2005-12-21 2016-09-28 Amgen Res Munich Gmbh Composições farmacêuticas com resistência a cea solúvel
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2009088105A1 (en) * 2008-01-11 2009-07-16 Gene Techno Science Co., Ltd. HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF
AU2009211340B2 (en) * 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CN106336400A (zh) * 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
CA2747534C (en) * 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
BRPI1008692B8 (pt) * 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
KR20120088550A (ko) 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
AU2012252152B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US20140170136A1 (en) * 2011-05-06 2014-06-19 Nvip Pty Ltd. Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2528811A (en) * 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
PL3498732T3 (pl) * 2011-05-06 2022-02-28 Zoetis Services Llc Przeciwciała przeciw czynnikowi wzrostu nerwów oraz sposoby ich otrzymywania i zastosowania
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
GB2504889C (en) * 2011-05-06 2015-08-26 Nvip Pty Ltd Therapeutic canine immunoglobulins and methods of using the same
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
JP5376095B2 (ja) 2011-08-11 2013-12-25 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
SG11201408037SA (en) * 2012-06-08 2015-01-29 Glenmark Pharmaceuticals Sa Humanized anti-trka antibodies with amino acid substitutions
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
CA2936102A1 (en) * 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015120136A1 (en) 2014-02-05 2015-08-13 VM Oncology LLC Compositions of compounds and uses thereof
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
BR112017015760A2 (pt) 2015-01-23 2018-03-27 Gvk Biosciences Private Limited inibidores de quinase trka
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US11260124B2 (en) * 2015-05-22 2022-03-01 Astellas Pharma Inc. Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
CN113365697B (zh) * 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
KR102265434B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
TW202124442A (zh) * 2019-09-13 2021-07-01 大陸商北京軒義醫藥科技有限公司 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
CN117003868B (zh) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN112625128B (zh) * 2020-08-06 2022-11-08 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
AU2021382828A1 (en) * 2020-11-20 2022-10-06 Sunshine Lake Pharma Co., Ltd. Humanized anti-TrkA antibodies and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
ATE140027T1 (de) 1989-12-01 1996-07-15 Pharming Bv Herstellung rekombinanter polypeptide durch rinder und transgene methoden
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
WO1992008483A1 (en) 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
JPH06503722A (ja) 1990-11-30 1994-04-28 アボット・ラボラトリーズ 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
EP0578515A3 (en) * 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5747060A (en) 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE60044149D1 (de) 1999-08-06 2010-05-20 S I S S A Scuola Internaz Supe Transgene mäuse zur studierung von neurodegenerativen syndromen
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
HK1049184A1 (zh) * 2000-03-16 2003-05-02 Genentech, Inc. 具有增强抗凝血效能的抗组织因子抗体
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US7507799B2 (en) * 2001-05-25 2009-03-24 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
EP2340849A1 (en) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2500901A1 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (en) 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040131515A1 (en) * 2003-01-03 2004-07-08 Alexanian Ara J. Material heat treatment system and method statement regarding federally sponsored research or development
WO2004065560A2 (en) 2003-01-18 2004-08-05 Rinat Neuroscience Corp. Methods of screening for modulators of nerve growth factor
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
MEP31508A (hr) 2003-07-15 2010-10-10 Amgen Inc Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7522822B2 (en) * 2004-01-06 2009-04-21 Robert Trujillo Halogen lamp assembly with integrated heat sink
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EP2298345A3 (en) 2005-01-24 2012-03-21 MedImmune Limited Specific binding members for NGF
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
US7290968B1 (en) 2006-03-06 2007-11-06 Shih-Chang Wu Extension fixture for turning tool
MX2009006594A (es) 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
EP2141593A1 (en) 2008-07-02 2010-01-06 Telefonaktiebolaget L M Ericsson (Publ) Requirement dependent allocation of hardware units to applications
CA2782712A1 (en) 2010-02-03 2011-08-11 Morinaga Milk Industry Co., Ltd. Method for manufacturing aloe powder
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions

Also Published As

Publication number Publication date
PT2138512E (pt) 2012-03-05
JP2012126726A (ja) 2012-07-05
EP2308894A2 (en) 2011-04-13
US20110105727A1 (en) 2011-05-05
HUE027475T2 (en) 2016-09-28
US8246956B2 (en) 2012-08-21
IL176495A (en) 2014-05-28
CY1112611T1 (el) 2016-02-10
SI2138512T1 (sl) 2012-04-30
EP2138512B8 (en) 2012-03-14
JP4652341B2 (ja) 2011-03-16
CY1117303T1 (el) 2017-04-26
ITRM20030601A1 (it) 2005-06-25
CA2688944C (en) 2015-04-07
CN1906212B (zh) 2013-07-17
ATE534665T1 (de) 2011-12-15
AU2009245889B2 (en) 2012-12-13
WO2005061540A3 (en) 2005-09-22
DK2138512T3 (da) 2012-02-27
DK2218737T3 (en) 2016-02-29
US20090300780A1 (en) 2009-12-03
US20110105728A1 (en) 2011-05-05
US20150218264A1 (en) 2015-08-06
EP2218737B1 (en) 2015-12-02
AU2016269485A1 (en) 2017-01-05
BRPI0418202A (pt) 2007-04-17
US20110104164A1 (en) 2011-05-05
EP1709076B1 (en) 2012-05-23
DK1709076T3 (da) 2012-08-27
AU2012261567A1 (en) 2013-01-10
ES2559429T3 (es) 2016-02-12
EP2138512B1 (en) 2011-11-23
US20110191872A1 (en) 2011-08-04
ZA200605200B (en) 2009-08-26
AU2004303633A1 (en) 2005-07-07
AU2012261567B2 (en) 2016-09-08
CA2551796A1 (en) 2005-07-07
US8877491B2 (en) 2014-11-04
AU2009245889A1 (en) 2010-01-07
CA2551796C (en) 2015-11-03
HK1139697A1 (en) 2010-09-24
JP2009291211A (ja) 2009-12-17
SI2218737T1 (sl) 2016-03-31
WO2005061540A2 (en) 2005-07-07
EP1709076A2 (en) 2006-10-11
JP2015110601A (ja) 2015-06-18
US8257710B2 (en) 2012-09-04
CN1906212A (zh) 2007-01-31
EP2138512A1 (en) 2009-12-30
AU2004303633B2 (en) 2011-12-08
ES2377535T3 (es) 2012-03-28
CN101724070B (zh) 2015-07-08
HK1147268A1 (en) 2011-08-05
IL220128A0 (en) 2012-07-31
JP2008500274A (ja) 2008-01-10
IL176495A0 (en) 2006-10-05
US8296079B2 (en) 2012-10-23
PT2218737E (pt) 2016-03-18
US20140316113A1 (en) 2014-10-23
EP2308894A3 (en) 2011-05-11
PL2218737T3 (pl) 2016-09-30
EP2218737A2 (en) 2010-08-18
CN101724070A (zh) 2010-06-09
CA2688944A1 (en) 2005-07-07
EP2218737A3 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
SI2218737T1 (sl) Humanizirana anti-NGF protitelesa
IN2009KN02655A (pl)
TR200200735T2 (tr) CTLA-4 için insan monoklonal antikorları
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
EP1461428A4 (en) HYBRID ANTIBODIES
WO2003087131A3 (en) Anti-her2 antibody variants
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2003068801A3 (en) Antibody variants with faster antigen association rates
WO2006039258A3 (en) Human antibodies against parathyroid hormone
ATE452147T1 (de) Antikörper mit korrigierten cdr
EP1491555A4 (en) THE GENE FOR THE LIGHT / HEAVY CHAIN OF THE VARIABLE REGION OF THE MONOCLONAL ANTI-HUMAN HEPATOMAN TONOR HAB18
WO2004085478A3 (en) Improved fc fusion proteins
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
WO2005047325A3 (en) Monkey immunoglobulin sequences
AP2006003532A0 (en) Anti-VEGF antibodies.